A CIRM Disease Team for the Treatment and Cure of Diabetes
This proposal is for the establishment of a group of faculty, staff and industrial partners to develop a proposal for a Diabetes Disease Team. Diabetes is one of the most…
Engineered matrices for control of lineage commitment in human pancreatic stem cells
Patients with end-stage type 1 diabetes (T1D) can be effectively managed by allogeneic islet transplantation. However, a severe cadaveric organ shortage greatly limits use of this promising procedure. Stem cells…
Generation of a functional thymus to induce immune tolerance to stem cell derivatives
Stem cell research offers the promise of replacing missing or damaged tissues in the treatment of disease. Stem-cell-derived transplants still face problems with rejection as in traditional organ transplants. Several…
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes
Diabetes exacts a tremendous toll on patients, their families, and society. Autoimmune Type 1 diabetes, often called juvenile-onset diabetes, is caused by a person’s own immune system mistakenly destroying their…
Deciphering transcriptional control of pancreatic beta-cell maturation in vitro
The loss of pancreatic beta-cells in type 1 diabetes results in absence of insulin secreted by the pancreas, and consequently elevated blood sugar which leads to various long-term complications. Diabetic…
Diabetes: Progress toward stem cell therapies, a Live Google Hangout
California's Stem Cell Agency (CIRM) hosted a live Google Hangout about recent progress in stem cell based strategies for diabetes therapies. The speakers included: Francisco Prieto, MD - CIRM's…